YF
CATX icon

Yu Fan’s Perspective Therapeutics CATX Stock Holding History

Yu Fan’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.6M Hold
1,055,409
– – 3.33% 7
2026
Q1 		$4.4M Buy
+1,055,409
New +$4.46M 4.54% 6

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Yu Fan's CATX Position: Q2 2026 in Review

Yu Fan held its Perspective Therapeutics (CATX) position steady in Q2 2026 at 1,055,409 shares worth $3.6M. The position accounts for 3.33% of the portfolio, ranked #7.

Yu Fan first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.4M in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Yu Fan held 1,055,409 shares of Perspective Therapeutics worth $3.6M as of Q2 2026.
  • Yu Fan left its Perspective Therapeutics share count unchanged in Q2 2026.
  • Perspective Therapeutics made up 3.33% of Yu Fan's portfolio in Q2 2026, its #7 holding.
  • Yu Fan first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Yu Fan's Perspective Therapeutics position peaked at $4.4M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Yu Fan's 13F filing for Q2 2026, filed 14 Aug 2026.